{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:21:38Z","timestamp":1787840498987,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A prospective longitudinal study was planned to assess immunogenicity, safety, and breakthrough infection rates among health care workers (HCWs) after COVISHIELD\u2122 vaccination in a teaching institute in North India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 518 HCWs were enrolled at baseline for receiving first dose of COVISHIELD\u2122, 429 continued participation for second dose, 415 followed up at 28 days after second dose, 405 at 6 months, and 403 at 1 year from February 2021 to November 2022. At each visit prior, 2 ml of blood sample was collected and plasma separated. Anti\u2013SARS-Cov-2 IgG antibodies against spike protein were detected by Chemiluminescent Immuno-Assay on the VITROS 3600 platform (Ortho-clinical Diagnostics, NJ, USA). Data were analysed for 403 HCWs (completed all follow-ups), using Statistical Package for Social Sciences version 21.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean age of participants was 35.3 years (SD \u00b1 11.11), and males were 50.2%. At baseline (N = 518), proportion of reactive HCWs was 25% (95% CI, 21\u201329%), which increased significantly to 92% (95% CI, 89\u201395%) after receiving first dose (N = 403), 95% (95% CI, 92\u201396%) after second dose (N = 403), and declined to 85% (95% CI, 83\u201393%) at six months (N = 403). At 1 year, reactivity increased to 89.3% (95% CI, 86\u201390%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.0001). Fever was reported by 31.2% of HCWs, followed by pain at injection site (27.6%), malaise (16.4%), headache (3.7%), and dizziness (3.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Immunogenicity post-COVISHIELD\u2122 vaccination increased after first and second doses but declined after 6 months and inclined after 1 year of the first dose. The safety profile was within acceptable limits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_935_24","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:04:02Z","timestamp":1740035042000},"page":"655-661","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety, immunogenicity, and breakthrough infections during 1-year follow-up after COVISHIELD\u2122 vaccination among healthcare workers in a teaching institute in North India: A prospective longitudinal study"],"prefix":"10.4103","volume":"14","author":[{"given":"Madhu","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrakshi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mini. P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Virology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Virology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritin","family":"Mohindra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Suri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Devnani","sequence":"additional","affiliation":[{"name":"Hospital Administration, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Verma","sequence":"additional","affiliation":[{"name":"Advanced Pediatric Centre, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOX1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.2021.19996","article-title":"Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in individuals with or without prior infection","volume":"326","author":"Zhong","year":"2021","journal-title":"JAMA"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41467-021-21111-9","article-title":"Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers","volume":"12","author":"Marot","year":"2021","journal-title":"Nat Commun"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jpm.2008.9690","article-title":"Study design, precision, and validity in observational studies","volume":"12","author":"Carlson","year":"2009","journal-title":"J Palliat Med"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.2147\/IDR.S362848","article-title":"Persistence of anti-SARS-CoV-2 Spike IgG antibodies following COVID-19 vaccines","volume":"15","author":"Alharbi","year":"2022","journal-title":"Infect Drug Resist"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"23259582221077943","DOI":"10.1177\/23259582221077943","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies among HIV infected individuals attending ART centre at Pune: A cross-sectional study","volume":"21","author":"Ghate","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"114299","DOI":"10.1016\/j.jviromet.2021.114299","article-title":"Performance evaluation of automated chemiluminescence immunoassay based antigen detection \u2013Moving towards more reliable ways to predict SARS-CoV-2 infection","volume":"298","author":"Paul","year":"2021","journal-title":"J Virol Methods"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"928501","DOI":"10.3389\/fimmu.2022.928501","article-title":"Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital","volume":"13","author":"Arankalle","year":"2022","journal-title":"Front Immunol"},{"key":"R16-20260109","first-page":"e46370","article-title":"Immunogenicity of ChAdOx1 (Covishield) booster dose in healthcare providers: A pre-post study","volume":"15","author":"Meher","year":"2023","journal-title":"Cureus"},{"key":"R17-20260109","first-page":"MO14","article-title":"Declining effect in the immunogenicity of Covishield vaccine among healthcare workers postvaccination-A prospective cohort study","volume":"13","author":"Gaurav","year":"2024","journal-title":"Natl J Lab Med"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"e160565","DOI":"10.1172\/JCI160565","article-title":"Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months","volume":"132","author":"Sobieszczyk","year":"2022","journal-title":"J Clin Invest"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4103\/ijmr.ijmr_1771_21","article-title":"Safety, immunogenicity and effectiveness of the COVID-19 vaccine among healthcare workers in a tertiary care hospital","volume":"155","author":"Kataria","year":"2022","journal-title":"Indian J Med Res"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"104217","DOI":"10.1016\/j.ebiom.2022.104217","article-title":"Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1\/2 and phase-2 clinical trials","volume":"83","author":"Thuluva","year":"2022","journal-title":"eBioMedicine"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1038\/s41467-021-27410-5","article-title":"Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England","volume":"12","author":"Amirthalingam","year":"2021","journal-title":"Nat Commun"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"e1009978","DOI":"10.1371\/journal.pcbi.1009978","article-title":"Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2","volume":"18","author":"Ferreira","year":"2022","journal-title":"PLOS Comput Biol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_935_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:01Z","timestamp":1787837041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_935_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_935_24","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}